Skip to main content
. 2017 Feb 6;2017:5672523. doi: 10.1155/2017/5672523

Figure 1.

Figure 1

The number of CD8+ (a), CD4+ T cells (b), CD19+ B cells (c), and CD56+/CD16+ NK cells (d) pre-DES and posttransplant in 36 DES patients who received DES with IVIg + rituximab followed by a kidney transplant with alemtuzumab induction. Each line with each symbol describes the result from one patient. The results were expressed as the ratio against the pre-DES level in each patient. DES: desensitization; Tx: transplant.